U.S. Markets closed

Marsh & McLennan (MMC) Q2 Earnings & Revenues Beat Estimates

Zacks Equity Research

Marsh & McLennan Companies, Inc. MMC delivered second-quarter 2019 adjusted earnings per share of $1.18, surpassing the Zacks Consensus Estimate by 4.4% on the back of higher revenues. Also, the bottom line improved 7.3% year over year.

Moreover, Marsh & McLennan’s consolidated revenues were $4.3 billion, up 16% on an underlying basis. This upside is majorly attributable to the Risk and Insurances Services plus Consulting Segments. Further, the top line slightly beat the Zacks Consensus Estimate by 0.3%.

Meanwhile, total operating expenses of $3.7 billion in the second quarter were up 20.6% year over year due to high compensation and benefits plus other operating expenses.

Marsh & McLennan Companies, Inc. Price, Consensus and EPS Surprise

Marsh & McLennan Companies, Inc. Price, Consensus and EPS Surprise

Marsh & McLennan Companies, Inc. price-consensus-eps-surprise-chart | Marsh & McLennan Companies, Inc. Quote

Quarterly Segmental Results

Risk and Insurance Services

Revenues at the Risk and Insurance Services segment were $2.6 billion, up 3% on an underlying basis. Adjusted operating income was up 21% to $641 million from the prior-year quarter’s level.

Marsh, a unit within this segment, generated revenues of $2.2 billion, up 4% on an underlying basis. In U.S./Canada, underlying revenues rose 5%. Underlying revenue growth from international operations includes 7% of the metric in Asia Pacific, flat in EMEA and 4% in Latin America.

Another unit under this segment — Guy Carpenter — displayed 3% revenue decline on an underlying basis to $392 million in the quarter under review.

Consulting

The Consulting segment's revenues rose 5% on an underlying basis. Also, adjusted operating income increased 14% year over year to $305 million.

A unit within this segment — Mercer — reported revenues of $1.3 billion, up 2% on an underlying basis. Wealth’s revenues were flat on an underlying basis.

Another unit, Oliver Wyman Group, registered revenues of $540 million, up 13% on an underlying basis.

Financial Update

Marsh & McLennan exited the quarter with cash and cash equivalents of nearly $1.3 billion, up 21.4% from the figure at 2018 end.

As of Jun 30, 2019, Marsh & McLennan’s total assets were $32.1 billion, up 49% from the tally at year-end 2018.

Total equity was $8.3 billion, up 10% from the level at year-end 2018.

Business Update

The company completed the pending buyout of Jardine Lloyd Thompson Group (JLT) in April 2019.

Share Repurchase and Dividend Update

The company bought back shares worth $100 million in the second quarter. In May, its board of directors also announced a 10% quarterly dividend hike effective the third quarter.

Zacks Rank

Marsh & McLennan carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Performance of Other Insurers

Of the insurance industry players that have already reported second-quarter results, the bottom-line figures of The Progressive Corporation PGR and RLI Corp. RLI beat the respective Zacks Consensus Estimate. However, The Travelers Companies, Inc.’s TRV earnings missed the consensus mark.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.

This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.

See their latest picks free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Marsh & McLennan Companies, Inc. (MMC) : Free Stock Analysis Report
 
The Travelers Companies, Inc. (TRV) : Free Stock Analysis Report
 
The Progressive Corporation (PGR) : Free Stock Analysis Report
 
RLI Corp. (RLI) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research